Events and Presentations

Arthur Lahr, Chief Executive Officer, will begin with a brief corporate overview which will be followed by a presentation from Dean Lee, MD, PhD – Hematology and Oncology at Nationwide Children’s Hospital and Director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital, The Ohio State U Comprehensive Cancer Center.

 

Kiadis Pharma will hold its Annual General Meeting (“AGM”) of shareholders at 10:00 (CEST) on Monday 24 June 2019 at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands.

Kiadis Pharma N.V. has convened an extraordinary general meeting of shareholders (“EGM”) to obtain shareholder approval pursuant to section 2:107a of the Dutch Civil Code for the proposed acquisition of CytoSen Therapeutics, Inc. that was announced earlier today. The EGM is to be held on Wednesday, May 29, 2019 at 10:00am CEST at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands. On the registration date (registratiedatum) for the EGM, Kiadis Pharma N.V. had 24,345,076 shares issued, each representing one vote.

Kiadis Pharma N.V. has convened an extraordinary general meeting of shareholders (“EGM”) to be held on Friday 29 March 2019 at 10:00 CET at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands.

Kiadis Pharma held its Annual General Meeting (AGM) of Shareholders on Monday 4 June 2018 at 10:00 CEST at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands.